Skip to content
DataLookout
Menu

NCT05904717

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

StatusCompleted
PhasePhase 2
SponsorSyntara
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 30, 2024 to Jul 31, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 55 words
    • Trial completed
    • Study completion date changed from estimate of Sep 30, 2026 to Sep 14, 2026
    • Site details revised at 1 of 3 sites
  2. Minor Study completion date: Jan 31, 2026 to Sep 30, 2026v4
  3. Notable Eligibility criteria expanded, about 100 words
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 2 to 3
    • Study completion date: Jan 31, 2025 to Jan 31, 2026
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to Nov 8, 2023
    • Site details revised at 2 of 2 sites
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To assess the reduction of microglial activation across striato-cortical regions
Timeframe: Up to Week 12
To assess the safety and tolerability of PXS-4728A as determined by adverse events (AEs)
Timeframe: Up to Week 24

Secondary (1)

To assess the reduction of microglial activation across the whole brain and cortical and subcortical regions of interest (ROIs)

Arms and interventions

A (PXS-4728)Experimental

IP Name: PXS-4728 Dosage: 15 mg Mode: oral administration (PO)

B (Matching Placebo)Placebo comparator

Matching placebo to PXS-4728

Drugs: PXS-4728 (A), Matching Placebo (B)

Sites

3 sites in 2 countries

Australia 2, United Kingdom 1